Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Michael Chi sold 2,100 shares of the stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $56.52, for a total transaction of $118,692.00. Following the transaction, the insider owned 291,439 shares of the company's stock, valued at $16,472,132.28. This represents a 0.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Michael Chi also recently made the following trade(s):
- On Wednesday, September 17th, Michael Chi sold 13,749 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50.
- On Monday, September 15th, Michael Chi sold 4,150 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.00, for a total transaction of $232,400.00.
- On Thursday, July 24th, Michael Chi sold 2,100 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.52, for a total transaction of $120,792.00.
- On Wednesday, July 23rd, Michael Chi sold 13,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.00, for a total transaction of $770,000.00.
Hims & Hers Health Price Performance
Shares of Hims & Hers Health stock traded up $1.69 on Thursday, reaching $54.94. The stock had a trading volume of 22,224,079 shares, compared to its average volume of 32,960,660. Hims & Hers Health, Inc. has a 1 year low of $16.05 and a 1 year high of $72.98. The company has a market cap of $12.42 billion, a P/E ratio of 68.68, a price-to-earnings-growth ratio of 3.78 and a beta of 2.14. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The business's 50 day moving average is $50.97 and its two-hundred day moving average is $46.04.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company's quarterly revenue was up 72.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on the stock. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Canaccord Genuity Group reiterated a "buy" rating and issued a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, UBS Group set a $30.00 price objective on Hims & Hers Health in a report on Monday, June 23rd. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Reduce" and an average target price of $38.92.
Check Out Our Latest Report on Hims & Hers Health
Hedge Funds Weigh In On Hims & Hers Health
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in Hims & Hers Health by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company's stock worth $236,622,000 after acquiring an additional 71,593 shares during the last quarter. Invesco Ltd. lifted its stake in Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock worth $127,237,000 after acquiring an additional 2,128,587 shares during the period. Northern Trust Corp lifted its position in Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock valued at $71,969,000 after buying an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd lifted its position in Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after buying an additional 700,100 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Hims & Hers Health in the 1st quarter worth about $58,403,000. 63.52% of the stock is currently owned by institutional investors.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
